Cargando…

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment

Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gounant, Valérie, Brosseau, Solenn, Zalcman, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669877/
https://www.ncbi.nlm.nih.gov/pubmed/34917175
http://dx.doi.org/10.1177/17588359211061956
_version_ 1784614867946176512
author Gounant, Valérie
Brosseau, Solenn
Zalcman, Gérard
author_facet Gounant, Valérie
Brosseau, Solenn
Zalcman, Gérard
author_sort Gounant, Valérie
collection PubMed
description Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as well as BAP-1tumor-suppressor genes, which usually regulate apoptosis, cell invasion, motility, cell division, chromatin remodeling, as well as control of DNA repair. In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term results. For about 15 years, first-line chemotherapy has been primarily based on a doublet of pemetrexed and cisplatin. Adding the monoclonal antibody bevacizumab (Avastin(®)), which targets vascular endothelial growth factor (VEGF), has been shown to improve overall survival (OS) by nearly 19 months. The emergence of immune check-point inhibitors (ICIs) in MPM treatment has recently been associated with substantial survival improvements in both second- and first-line settings. Similarly to non-small-cell lung cancer (NSCLC) patients, on-going trials are presently exploring the chemotherapy-ICI combination in MPM management, and depending on their results, this combination could represent a further major advance in this previously orphan disease. The current article reviews recent clinical trial results, as well as future clinical developments in this moving field.
format Online
Article
Text
id pubmed-8669877
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86698772021-12-15 Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment Gounant, Valérie Brosseau, Solenn Zalcman, Gérard Ther Adv Med Oncol Review Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as well as BAP-1tumor-suppressor genes, which usually regulate apoptosis, cell invasion, motility, cell division, chromatin remodeling, as well as control of DNA repair. In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term results. For about 15 years, first-line chemotherapy has been primarily based on a doublet of pemetrexed and cisplatin. Adding the monoclonal antibody bevacizumab (Avastin(®)), which targets vascular endothelial growth factor (VEGF), has been shown to improve overall survival (OS) by nearly 19 months. The emergence of immune check-point inhibitors (ICIs) in MPM treatment has recently been associated with substantial survival improvements in both second- and first-line settings. Similarly to non-small-cell lung cancer (NSCLC) patients, on-going trials are presently exploring the chemotherapy-ICI combination in MPM management, and depending on their results, this combination could represent a further major advance in this previously orphan disease. The current article reviews recent clinical trial results, as well as future clinical developments in this moving field. SAGE Publications 2021-12-10 /pmc/articles/PMC8669877/ /pubmed/34917175 http://dx.doi.org/10.1177/17588359211061956 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Gounant, Valérie
Brosseau, Solenn
Zalcman, Gérard
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title_full Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title_fullStr Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title_full_unstemmed Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title_short Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
title_sort immunotherapy, the promise for present and future of malignant pleural mesothelioma (mpm) treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669877/
https://www.ncbi.nlm.nih.gov/pubmed/34917175
http://dx.doi.org/10.1177/17588359211061956
work_keys_str_mv AT gounantvalerie immunotherapythepromiseforpresentandfutureofmalignantpleuralmesotheliomampmtreatment
AT brosseausolenn immunotherapythepromiseforpresentandfutureofmalignantpleuralmesotheliomampmtreatment
AT zalcmangerard immunotherapythepromiseforpresentandfutureofmalignantpleuralmesotheliomampmtreatment